Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to report earnings per share of ($0.51) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ADMA Biologics’ earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.70). ADMA Biologics posted earnings of ($0.35) per share in the same quarter last year, which would suggest a negative year over year growth rate of 45.7%. The business is scheduled to announce its next earnings report on Friday, February 23rd.
According to Zacks, analysts expect that ADMA Biologics will report full year earnings of ($2.28) per share for the current fiscal year, with EPS estimates ranging from ($2.73) to ($1.76). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.25) to ($0.93). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover ADMA Biologics.
A number of brokerages have issued reports on ADMA. Maxim Group restated a “buy” rating and set a $8.00 target price (down previously from $13.00) on shares of ADMA Biologics in a report on Monday, December 11th. Raymond James Financial upgraded ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Tuesday, November 14th.
ADMA Biologics (ADMA) opened at $3.71 on Friday. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. ADMA Biologics has a 1-year low of $2.01 and a 1-year high of $5.44. The stock has a market capitalization of $95.69, a PE ratio of -1.86 and a beta of 2.17.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/10/analysts-expect-adma-biologics-inc-adma-will-announce-earnings-of-0-51-per-share.html.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.